Kevin T Conroy Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 days, 12 hours ago
Kevin T Conroy has an estimated net worth of at least $77.0 million*, as of Jan. 29, 2025. They own 1.1 million shares of EXAS stock. They have sold 216,511 shares of EXAS stock since 2021, for an estimated $16.2 million.
Kevin T Conroy $EXAS SEC Form 4 Insider Trading
Kevin T Conroy has filed a total of 21 insider trades in $EXAS since 2021. Their most recent trade was a purchase of 19,500 shares, made on Nov 13, 2024. Their largest trade was a sale of 27,126 shares, made on Feb 24, 2022. We estimate that they now own 1.1 million shares of $EXAS, worth an estimated $60.8 million.
Insider Trading at $EXAS
There have been a total of 141 insider trades reported at $EXAS since 2021, with 19,500 shares purchased and 528,616 shares sold. The most active insider traders in $EXAS stock have been Jeffrey Thomas Elliott, Sarah Condella, and Kevin T Conroy. The most recent trade was a purchase of 19,500 shares reported by Kevin T Conroy (President and CEO), made on Nov 13, 2024.
History of Insider Stock Trades by Kevin T Conroy
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
EXAS
|
Purchase | 19,500 | Nov 13, 2024 | Nov. 13, 2024, 1:56 p.m. |
|
EXAS
|
Sale | 1,155 | May 01, 2024 | May 2, 2024, 7 p.m. |
|
EXAS
|
Sale | 8,271 | Mar 01, 2024 | March 4, 2024, 9:38 p.m. |
|
EXAS
|
Sale | 6,263 | Feb 27, 2024 | Feb. 28, 2024, 8:35 p.m. |
|
EXAS
|
Sale | 11,565 | Feb 22, 2024 | Feb. 23, 2024, 8:59 p.m. |
|
EXAS
|
Sale | 4,975 | Feb 21, 2024 | Feb. 22, 2024, 8:37 p.m. |
|
EXAS
|
Sale | 14,791 | Feb 15, 2024 | Feb. 16, 2024, 7:22 p.m. |
|
EXAS
|
Sale | 10,416 | Feb 28, 2023 | March 1, 2023, 6:15 p.m. |
|
EXAS
|
Sale | 4,764 | Feb 22, 2023 | Feb. 23, 2023, 5:35 p.m. |
|
EXAS
|
Sale | 14,617 | Feb 15, 2023 | Feb. 16, 2023, 6:05 p.m. |
|
EXAS
|
Sale | 4,527 | Feb 13, 2023 | Feb. 14, 2023, 6:40 p.m. |
|
EXAS
|
Sale | 7 | Jul 01, 2022 | July 6, 2022, 4:11 p.m. |
|
EXAS
|
Sale | 14,299 | Mar 01, 2022 | March 2, 2022, 6:28 p.m. |
|
EXAS
|
Sale | 27,126 | Feb 24, 2022 | Feb. 25, 2022, 7:40 p.m. |
|
EXAS
|
Sale | 5,188 | Feb 23, 2022 | Feb. 24, 2022, 8:14 p.m. |
|
EXAS
|
Sale | 14,409 | Feb 15, 2022 | Feb. 16, 2022, 9:08 p.m. |
|
EXAS
|
Sale | 16,922 | Nov 01, 2021 | Nov. 2, 2021, 8 p.m. |
|
EXAS
|
Sale | 17,078 | Oct 01, 2021 | Oct. 4, 2021, 8 p.m. |
|
EXAS
|
Sale | 19,970 | Aug 02, 2021 | Aug. 3, 2021, 8 p.m. |
|
EXAS
|
Sale | 7,784 | Jul 01, 2021 | July 5, 2021, 8 p.m. |
|
EXAS
|
Sale | 12,384 | Jun 01, 2021 | June 2, 2021, 8 p.m. |
$EXAS Executives and Stock Owners with Insider Trades
-
Jeffrey Thomas Elliott, Chief Financial Officer
-
Sarah Condella, EVP, Human Resources
-
Kevin T Conroy, President and CEO
-
Jacob A Orville, General Manager, Screening
-
James Herriott, General Counsel
-
Brian Baranick, Gen. Mgr., Precision Oncology
-
Everett Cunningham, Chief Commercial Officer
-
Sarah Condella, SVP, Human Resources
-
Jacob A Orville, General Manager, New Ventures
-
D Scott Coward, Chief Administrative Officer
-
Brian Baranick, EVP, GM, Precision Oncology
-
Brian Baranick, EVP, GM., Precision Oncology
-
D Scott Coward, Chief Legal Officer
-
James Herriott, SVP, General Counsel & Sec
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.